Cancer Specialty
Conference Coverage
- ASCO
- AACR 2024
- ASCO GI 2024
- ASH 2023
- SABCS 2023
- MOASC
- ASCO 2023

Advertisement

X (Twitter) LinkedIn Facebook

X (Twitter) LinkedIn Facebook

Cancer Specialty
Conference Coverage
- ASCO
- AACR 2024
- ASCO GI 2024
- ASH 2023
- SABCS 2023
- MOASC
- ASCO 2023

Home » Dr. Jean Jacques Kiladjian ASH 2018 interview with David Wallace, PV Reporter, part 2

Myeloproliferative Disease

Dr. Jean Jacques Kiladjian ASH 2018 interview with David Wallace, PV Reporter, part 2

By EditorJanuary 4, 2019No Comments1 Min Read

Twitter LinkedIn Facebook Email

Share

Twitter LinkedIn Facebook Email

Dr. J.J. Kiladjian ASH 2018 Headline Research Studies

Follow on X (Twitter) Follow on LinkedIn Follow on Facebook Follow on Google News

Share. Twitter LinkedIn Facebook Email

Related Posts

Spotlight on Myelofibrosis 2024: The Critical Evolution of JAK Inhibitors

Myeloproliferative Disease 3 Mins Read

Rusfertide: A New Horizon in Polycythemia Vera Treatment?

Hematologic Malignancies 7 Mins Read

Prognostic Models in Myelofibrosis Management Slides 2023

Myeloproliferative Disease 4 Mins Read

Advertisement Sidebar

Recent Posts

BRCA Carriers Slicing Breast Cancer Odds: Does Surgery Lead to Longevity Leaps?
Palbociclib (IBRANCE) Revs Up Metastatic Breast Cancer in PATINA Results
Atezolizumab Stumbles in Triple Negative Breast Cancer Study: SABCS 2024 Results with Charles Geyer
Metastatic Breast Cancer: Trastuzumab (Herceptin) Factors for Long-Term Remission in HER2 negative
Breast Cancer New Nemeses: CDK4/6 Inhibitors Rave Against Recurrence, But Have They Crashed the EBC Party in NATALEE & monarchE’s Real-World Dance-Off?

Connect With Us on Social

Facebook
Twitter
LinkedIn

X (Twitter) LinkedIn Facebook

© 2024 Copyright Protected Medicus Networks, Inc..

Type above and press Enter to search. Press Esc to cancel.